AI may foresee lung complications after liver surgery

NCT ID NCT07070362

NEW Recruiting now Knowledge-focused Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early and make better treatment decisions. The research will involve 3000 adult patients having major liver surgery, such as hepatectomy or liver transplantation, and will track whether they develop ALI within 7 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a digital tool that helps doctors predict and prevent acute lung injury after major liver surgery, potentially reducing complications and deaths.
What could go wrong: This is an observational study, so it won't test a treatment. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LUNG INJURY(ALI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome adult acute respiratory distress syndrome cirrhosis of liver hepatocellular carcinoma liver cancer metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LUNG INJURY(ALI) ARDS, HUMAN LIVER CANCER, ADULT LIVER CIRRHOSIS MASLD MASLD/MASH (METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE / METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS) NAFLD (NONALCOHOLIC FATTY LIVER DISEASE)

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine，Tsinghua University
RECRUITING

Beijing, Beijing Municipality, 102218, China
Huangdao District People's Hospital of Qingdao
RECRUITING

Qingdao, China
Peking University International Hospital
RECRUITING

Beijing, China
Southwest Hospital, The First Affiliated Hospital of Army Medical University
RECRUITING

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.